US5900246A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Drug incorporating and releasing polymeric coating for bioprosthesis
Assignee: Cedars-Sinai Medical Center
•
Filing: 1995-06-05
•
Granted: 1999-05-04
•
Expires: 2015-06-05
Abstract
Abstract In accordance with the present invention, there are provided prosthetic articles having polyurethane coatings with biologically active compounds incorporated within the interstices of the polymer. Methods for the preparation of such articles are also provided. Thus, a polyurethane coating is applied to a prosthetic article, the coating then swelled (without significantly dissolving the polymer) so that substantial quantities of biologically active compounds can be incorporated within the interstices of the polymer. Upon long term exposure of a prosthetic article of the invention to physiological conditions, the biologically active compound is slowly released by the treated polymer. The biologically active compound is, therefore, released only at the site where it is desired, i.e., where the prosthetic article is positioned.
Inventors
- 👤 Thomas L. Lambert
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-22 23:55
CPC Classifications
A; A61; A61L; A61L31/00; A61L31/14; A61L31/16; A61L27/00; A61L27/28; A61L27/34; A61L27/50; A61L27/54; A61L29/00; A61L29/08; A61L29/085; A61L29/14; A61L29/16; A61L31/08; A61L31/10; A61L2300/00; A61L2300/60; A61L2300/606; A61M; A61M25/00; A61M25/0043; A61M2025/0057; A61M25/10; A61M25/104; A61M31/00; A61M31/002
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
121 words
A drug delivery system for localized delivery of a biologically active compound to a subject, comprising: a substrate having coated thereon a medical grade, linear, aliphatic polyurethane elastomer and at least one biologically active compound absorbed into the interstices of said coating, wherein said substrate is selected from the group consisting of a stent, a prostheses, a heart valve, a pacemaker, a catheter, a balloon, an ocular implant, and a contact lens, wherein said linear aliphatic polyurethane elastomer coating has a thickness of at least 20 microns, wherein said linear, aliphatic polyurethane elastomer coating is the reaction product of a) polytetramethylene ether glycol, b) an aliphatic diisocyanate, and c) a chain extender, and wherein said chain extender is an aliphatic diol.
Claim 2
Dependent Claim
121 words
A drug delivery system for localized delivery of a biologically active compound to a subject, comprising: a substrate having coated thereon a medical grade, linear, aliphatic polyurethane elastomer and at least one biologically active compound absorbed into the interstices of said coating, wherein said substrate is selected from the group consisting of a stent, a prostheses, a heart valve, a pacemaker, a catheter, a balloon, an ocular implant, and a contact lens, wherein said linear aliphatic polyurethane elastomer coating has a thickness of at least 20 microns, wherein said linear, aliphatic polyurethane elastomer coating is the reaction product of a) polytetramethylene ether glycol, b) an aliphatic diisocyanate, and c) a chain extender, and wherein said chain extender is an aliphatic diol.
Claim 3
Dependent Claim
23 words
The drug delivery system of claim 1 wherein the biological agent is absorbed substantially throughout the entire thickness of the polyurethane elastomer coating.
Claim 4
Dependent Claim
25 words
The drug delivery system of claim 2 wherein the polyurethane polymer coating has a thickness in the range of about 25 up to 500 microns.
Claim 5
Dependent Claim
25 words
The drug delivery system of claim 3, wherein the polytetramethylene ether glycol has a molecular weight in the range of about 500 to about 5000.
Claim 6
Dependent Claim
26 words
The drug delivery system of claim 4, wherein the ratio of chain extender to polytetramethylene ether glycol is in the range of about 1:1 to 5:1.
Claim 7
Dependent Claim
15 words
The drug delivery system of claim 5, wherein the chain extender is 1,4 butane diol.
Claim 8
Dependent Claim
28 words
The drug delivery system of claim 6, wherein said aliphatic diisocyanate is selected from the group consisting of hexamethylene diisocyanate, isophorone diisocyanate, trimethyl hexamethylene diisocyanate, and dicyclohexylmethane diisocyanate.
Claim 9
Dependent Claim
14 words
The drug delivery system of claim 7, wherein the aliphatic diisocyanate is dicyclohexylmethane diisocyanate.
Claim 10
Dependent Claim
16 words
The drug delivery system of claim 8, wherein said biologically active compound is a lipophilic compound.
Claim 11
Dependent Claim
26 words
The drug delivery system of claim 3, wherein the ratio of chain extender to polytetramethylene ether glycol is in the range of about 1:1 to 5:1.
Claim 12
Dependent Claim
15 words
The drug delivery system of claim 3, wherein the chain extender is 1,4 butane diol.
Claim 13
Dependent Claim
28 words
The drug delivery system of claim 3, wherein said aliphatic diisocyanate is selected from the group consisting of hexamethylene diisocyanate, isophorone diisocyanate, trimethyl hexamethylene diisocyanate, and dicyclohexylmethane diisocyanate.
Claim 14
Dependent Claim
14 words
The drug delivery system of claim 12, wherein the aliphatic diisocyanate is dicyclohexylmethane diisocyanate.
Claim 15
Dependent Claim
16 words
The drug delivery system of claim 3, wherein said biologically active compound is a lipophilic compound.
Claim 16
Dependent Claim
14 words
The drug delivery system of claim 3, wherein said prostheses is a prosthetic joint.
Claim 17
Dependent Claim
289 words
A drug delivery system for localized delivery of a biologically active compound to a subject, comprising: a substrate having coated thereon a medical grade, linear, aliphatic polyurethane elastomer and at least one biologically active compound absorbed into the interstices substantially throughout the entire thickness of said coating, wherein said substrate is selected from the group consisting of a stent, a prostheses, a heart valve, a pacemaker, a catheter, a balloon, an ocular implant, and a contact lens, wherein said linear, aliphatic polyurethane elastomer coating has a thickness in the range of about 25 up to 500 microns, wherein said linear, aliphatic polyurethane elastomer coating is the reaction product of a) polytetramethylene ether glycol, b) an aliphatic diisocyanate, and c) a chain extender, and wherein said chain extender is an aliphatic diol, and wherein said drug delivery system is prepared by treating the medical-grade, polyurethane polymer coating with a coating expansion solution at a temperature, under a pressure and for a time sufficient to cause the biologically active compound to penetrate into the interstices of the polymer coating, said coating expansion solution comprising the biologically active compound and an organic solvent system, wherein the organic solvent system comprises at least one solvent for the polymer coating and at least one non-solvent for the polymer coating, wherein the solvent and the non-solvent are present in the organic solvent system at a ratio of solvent to non-solvent in the range of about 1:1 to about 1:20 by volume, and wherein the biologically active compound is present in the coating expansion solution in a concentration of at least 0.1 parts per 100 parts of the organic solvent system; and then drying the thus treated polymer coating to substantially eliminate the organic solvent system.
Claim 18
Dependent Claim
289 words
A drug delivery system for localized delivery of a biologically active compound to a subject, comprising: a substrate having coated thereon a medical grade, linear, aliphatic polyurethane elastomer and at least one biologically active compound absorbed into the interstices substantially throughout the entire thickness of said coating, wherein said substrate is selected from the group consisting of a stent, a prostheses, a heart valve, a pacemaker, a catheter, a balloon, an ocular implant, and a contact lens, wherein said linear, aliphatic polyurethane elastomer coating has a thickness in the range of about 25 up to 500 microns, wherein said linear, aliphatic polyurethane elastomer coating is the reaction product of a) polytetramethylene ether glycol, b) an aliphatic diisocyanate, and c) a chain extender, and wherein said chain extender is an aliphatic diol, and wherein said drug delivery system is prepared by treating the medical-grade, polyurethane polymer coating with a coating expansion solution at a temperature, under a pressure and for a time sufficient to cause the biologically active compound to penetrate into the interstices of the polymer coating, said coating expansion solution comprising the biologically active compound and an organic solvent system, wherein the organic solvent system comprises at least one solvent for the polymer coating and at least one non-solvent for the polymer coating, wherein the solvent and the non-solvent are present in the organic solvent system at a ratio of solvent to non-solvent in the range of about 1:1 to about 1:20 by volume, and wherein the biologically active compound is present in the coating expansion solution in a concentration of at least 0.1 parts per 100 parts of the organic solvent system; and then drying the thus treated polymer coating to substantially eliminate the organic solvent system.
Claim 19
Dependent Claim
16 words
The drug delivery system of claim 16, wherein said biologically active compound is a lipophilic compound.
Claim 20
Dependent Claim
261 words
A drug delivery system for localized delivery of a biologically active compound to a subject, comprising: a substrate having coated thereon a medical grade, linear, aliphatic polyurethane elastomer and at least one biologically active compound absorbed into the interstices substantially throughout the entire thickness of said coating, wherein said substrate is selected from the group consisting of a stent, a prostheses, a heart valve, a pacemaker, a catheter, a balloon, an ocular implant, and a contact lens, wherein said linear, aliphatic polyurethane elastomer coating has a thickness in the range of about 25 up to 500 microns, wherein said linear, aliphatic polyurethane elastomer coating is the reaction product of a) polytetramethylene ether glycol, b) an aliphatic diisocyanate, and c) a chain extender, and wherein said chain extender is an aliphatic diol, and wherein said drug delivery system is prepared by treating the medical-grade, polyurethane polymer coating with a coating expansion solution at a temperature, under a pressure and for a time sufficient to cause the biologically active compound to penetrate into the interstices of the polymer coating, said coating expansion solution comprising the biologically active compound and an organic solvent system, wherein the organic solvent system comprises at least one solvent for the polymer coating and at least one non-solvent for the polymer coating, wherein the solvent and the non-solvent are present in the organic solvent system at a ratio of solvent to non-solvent in the range of about 1:1 to about 1:20 by volume, then drying the thus treated aliphatic polyurethane elastomer coating to substantially eliminate the organic solvent system.
Claim 21
Dependent Claim
261 words
A drug delivery system for localized delivery of a biologically active compound to a subject, comprising: a substrate having coated thereon a medical grade, linear, aliphatic polyurethane elastomer and at least one biologically active compound absorbed into the interstices substantially throughout the entire thickness of said coating, wherein said substrate is selected from the group consisting of a stent, a prostheses, a heart valve, a pacemaker, a catheter, a balloon, an ocular implant, and a contact lens, wherein said linear, aliphatic polyurethane elastomer coating has a thickness in the range of about 25 up to 500 microns, wherein said linear, aliphatic polyurethane elastomer coating is the reaction product of a) polytetramethylene ether glycol, b) an aliphatic diisocyanate, and c) a chain extender, and wherein said chain extender is an aliphatic diol, and wherein said drug delivery system is prepared by treating the medical-grade, polyurethane polymer coating with a coating expansion solution at a temperature, under a pressure and for a time sufficient to cause the biologically active compound to penetrate into the interstices of the polymer coating, said coating expansion solution comprising the biologically active compound and an organic solvent system, wherein the organic solvent system comprises at least one solvent for the polymer coating and at least one non-solvent for the polymer coating, wherein the solvent and the non-solvent are present in the organic solvent system at a ratio of solvent to non-solvent in the range of about 1:1 to about 1:20 by volume, then drying the thus treated aliphatic polyurethane elastomer coating to substantially eliminate the organic solvent system.
Claim 22
Dependent Claim
16 words
The drug delivery system of claim 18, wherein said biologically active compound is a lipophilic compound.
Claim 23
Dependent Claim
26 words
The drug delivery system of claim 18, wherein the ratio of chain extender to polytetramethylene ether glycol is in the range of about 1:1 to 5:1.
Claim 24
Dependent Claim
15 words
The drug delivery system of claim 18, wherein the chain extender is 1,4 butane diol.
References Cited (Backward Citations)
US32991A
Cited
US3585647A
Cited
US3853804A
Cited
US4292965A
Cited
US4447590A
Cited
US4582717A
Cited
US4879135A
Cited
USRE32991E
Cited
US4614787A
Cited
US4731080A
Cited
EP0207624A2
Cited
US4713402A
Cited
US4749585A
Cited
US4869909A
Cited
WO1989004682A1
Cited
US5019096A
Cited
US5053048A
Cited
US4925668A
Cited
US5451424A
Cited
US5183663A
Cited
EP0405284A2
Cited
US5118779A
Cited
US5066298A
Cited
WO1992011877A1
Cited
WO1992015286A1
Cited
EP0520160A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-05-03 | 2002-11-02 | 2003-05-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-05-03 | 2006-11-02 | 2007-05-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-05-03 | 2010-11-02 | 2011-05-04 | $7700.00 | Window Closed / Lapsed |